Abstract

Purpose  This analysis compares salvage lymph node dissection (SLND) to salvage lymph node radiotherapy (SLNRT) of 68Ga-PSMA PET-positive nodal recurrences after radical prostatectomy (RPE).

Methods  A total of 67 SLNRT and 33 SLND consecutive patients with pelvic and/or para-aortic nodal recurrences after RPE were retrospectively analyzed. Biochemical recurrence-free survival rates (bRFS; PSA <0.2 ng/mL) were calculated according to Kaplan–Meier and survival curves were compared using the log rank test. For multivariable analysis, binary logistic regression analysis was performed (p<0.05).

Results  Median follow-up was 17 months (range, 6–53 months) in SLND patients and 31 months (range, 3–56 months) in SLNRT patients (p=0.027). SLNRT patients had significantly more tumours of pT3 and pT4 category (82% vs. 67%; p=0.006), pathologically involved lymph nodes (45% vs. 27%; p=0.001) and positive surgical margins (54% vs. 12%; p=0.001) at time of RPE than SLND patients. PSA persistence after RPE was significantly more frequently observed in the SLNRT cohort (73% vs. 27%; p=0.001). There was no significant difference in the distribution of PET-positive lymph nodes. Median PSA before SLND was higher than before SLNRT (3.07 ng/ml vs. 1.3 ng/ml; p=0.393). The 2-year bRFS was significantly higher in the SLNRT vs. the SLND cohort (92% vs. 30%; p=0.001) with lower rates of distant metastases (21% vs. 52%; p=0.002) and secondary treatments (5% vs. 39%; p=0.011) irrespective of ongoing androgen deprivation therapy at last contact. In multivariable analysis, SLNRT was significantly associated with prolonged bRFS (regression coefficient 1.436, hazard ratio 4.204, 95% CI 1.789–9.878; p=0.001).

Conclusion  Based on this retrospective study SLNRT might be the preferred treatment option for patients with nodal recurrence after previous RPE.

Keywords  Prostate cancer · PSMA PET/CT · Biochemical recurrence · Biochemical persistence · Radiotherapy · Salvage lymph node dissection

Introduction

Up to 30% of patients with high-risk prostate cancer (PCa) relapse after radical prostatectomy (RPE) with the majority of patients having lymph node recurrences [1–3]. Manage-
of SLND varied significantly between the currently available studies, as did adjuvant treatment, endpoints, and study populations, and present evidence is mostly based on small single-centre case series [4].

Likewise, few studies on SLNRT were identified in a recent review: Patients with pelvic and/or extra-pelvic nodes were either treated by stereotactic body radiotherapy (SBRT) (55%) or elective nodal radiotherapy (ENRT) (45%) to a lymph node region or the whole pelvic lymphatic pathways [5]. In patients treated with ENRT 3-year progression-free survival ranged from 61.8 to 75% [6], whereas in patients with SBRT to PET-positive lymph nodes 3-year progression-free survival ranged between 26 and 33% [5]. This is strikingly comparable to outcome data achieved by SLND, although one has to reconsider that the majority of patients in the reported studies were staged at best with choline positron emission tomography/computer tomography (PET/CT) thus underestimating the true extent of nodal recurrence.

Hereby, a significant benefit for 68gallium-prostate-specific membrane antigen PET/CT (68Ga-PSMA PET/CT) was observed, and PSMA-PET/CT has since then evolved towards the new imaging reference standard with a high detection rate of lymph nodes in case of PSA persistence or recurrence [7–11]. This might improve outcome by enabling a more extended lymphadenectomy or a higher dose administration to PET-positive lymph nodes and at the same time a more comprehensive ENRT.

Thus, this current analysis was restricted to patients with PSMA PET-positive lymph node recurrences after RPE in order to compare SLND to SLNRT at a tertiary care centre.

**Materials and methods**

**Patient population**

Between February 2014 and December 2018, 100 consecutive patients underwent 68Ga-PSMA PET/CT prior to SLNRT (67 patients) or SLND (33 patients) with evidence of PET-positive pelvic and/or para-aortic lymph nodes after RPE. Patients who underwent previous adjuvant radiotherapy of the pelvic lymphatic pathways or ADT prior to SLNRT/SLND were excluded. Patients were subgrouped according to the D’Amico criteria [12] incorporating tumour-stage, PSA level and Gleason score (GS) (Table 1). All patients provided written informed consent to undergo 68Ga-PSMA PET/CT. This retrospective analysis was performed in compliance with the principles of the Declaration of Helsinki and its subsequent amendments [13].

**68Ga-PSMA labelling and PET/CT imaging**

Radiolabelling of PSMA-HBED-CC was performed with 68Ga from a 68Ge/68Ga generator system (GalliaPharm®, Eckert & Ziegler AG, Berlin, Germany) using an automated synthesis module (GRP, Scintomics GmbH, Munich, Germany) and prepacked cassettes (ABX GmbH, Radeberg, Germany) as described previously for a different PSMA ligand by Weineisen et al. [14]. 68Ga-PSMA PET/CT imaging was performed according to current guidelines [15] with a Siemens Biograph 64 or GE Discovery 690 PET/CT camera. Phantom studies based on the National Electrical Manufacturers Association NU2-2001 standard were conducted to allow valid pooling of the results, and standardized uptake value (SUV) conversion factors were calculated [16]. 68Ga-PSMA PET/CT scans were performed with a diagnostic CT scan (reference mAs, 200–240; 120 kV) and obtained with intravenous injection of iodine-containing contrast agent (Ultravist 300, Bayer Pharma AG, Berlin, Germany; or Imeron 300, Bracco, Konstanz; 2.5 mL/s; in portal venous phase) around 60 min after intravenous administration of 68Ga-PSMA. In absence of contraindications, 20 mg furosemide was injected almost simultaneously with 68Ga-PSMA injection to lower tracer retention in the bladder. PET images were reconstructed with an axial 168 × 168 matrix based on the TrueX algorithm (3 iterations, 21 subsets; Biograph 64) or on the VUE Point FX algorithm (2 iterations, 36 subsets; Discovery 690).

**Image interpretation**

PET/CT images were interpreted by a consensus read of two nuclear medicine physicians and two radiologists in the sense of a clinical report-based analysis. At least two of the readers had more than 10 years PET/CT experience. The location of each lesion was determined by CT. PET-positive lesions were visually identified by 68Ga-PSMA uptake above background level and not associated with physiologic uptake [15].

**Radiotherapy**

All patients received ENRT by intensity-modulated radiotherapy (IMRT) or volumetric arc therapy (VMAT) and image-guided radiotherapy techniques (IGRT, 2–5 times/week). Radiotherapy dose regimens were normo- or slightly hypofractionated and a boost to the PET-positive local recurrences within prostatic fossa and lymph nodes was applied simultaneously. The prostatic fossa was treated with a median of 66 Gy (range, 60–67.20 Gy) in single doses of 2 Gy (range, 1.8–2.12 Gy) and the elective lymphatic pathways with 50.4 Gy (range, 45–52.28 Gy) in single doses of 1.8 Gy (range, 1.6–1.8 Gy). PSMA PET-positive local re-
| Table 1  | Patients’ characteristics | SLND  | SLNRT  | p-value |
|----------|---------------------------|-------|--------|---------|
| Patients | n = 33                    | n = 67|        |         |
| Age (years) median (range) at time of LN dissection/RT | 66 (52–83) | 72 (47–83) | 0.151 |
| Initial PSA at RPE (ng/ml) median (range) | 10.40 (2.01–262) | 17.30 (3.99–190) | 0.334 |
| Gleason score | ≤6–7 | 20 (61%) | 28 (42%) | 0.059 |
| | 8–9 | 13 (39%) | 39 (58%) | |
| TNM at time of RPE | | | | 0.006 |
| T-stage | | | | |
| T2 | 11 (33%) | 12 (18%) | |
| T3–4 | 22 (67%) | 55 (82%) | |
| N-stage | | | | 0.001 |
| N0 | 17 (52%) | 36 (54%) | |
| N1 | 9 (27%) | 30 (45%) | |
| N x | 7 (21%) | 1 (1%) | |
| Number of removed LN median (range) | 11 (4–37) | 14 (2–45) | |
| Number of positive LN median (range) | 0 (0–5) | 0 (0–16) | |
| M0 | 33 (100%) | 67 (100%) | |
| Positive surgical margins | 4 (12%) | 36 (54%) | 0.001 |
| D’Amico classification | | | | 0.967 |
| Low | 1 (3%) | 2 (3%) | |
| Intermediate | 5 (15%) | 5 (7%) | |
| High | 27 (82%) | 60 (90%) | |
| Postoperative PSA median (range) | 0.30 (<0.03–10) | 0.59 (<0.03–58) | 0.642 |
| PSA persistence/recurrence | | | | 0.001 |
| Number of patients with PSA persistence | 9 (27%) | 49 (73%) | |
| Number of patients with PSA recurrence | 24 (73%) | 18 (27%) | |
| PSA at PET (ng/ml) median (range) | | | | |
| PSA persistence | 1.75 (0.21–19.50) | 1.60 (0.14–40.13) | 0.391 |
| PSA recurrence | 1.70 (0.30–16.0) | 0.67 (0.31–6.76) | 0.342 |
| PSMA PET/CT result | | | | 0.001 |
| Lymph node positive only | 33 (100%) | 51 (76%) | |
| Fossa and lymph node recurrence | 0 (0%) | 16 (24%) | |
| Number of PET-positive lymph nodes (median; range) | 1 (1–10) | 2 (1–19) | 0.392 |
| Distribution of suspect lymph nodes | | | | 0.063 |
| Pelvic | 25 (76%) | 54 (81%) | |
| Retropertioneal | 4 (12%) | 1 (1%) | |
| Both | 4 (12%) | 12 (18%) | |
| Time (months) between RPE and SLN dissection/RT start median (range) | | | | 0.941 |
| All patients | 9 (2–120) | 6 (2–194) | |
| PSA persistence | 7 (2–84) | 5 (2–86) | |
| PSA recurrence | 11 (2–120) | 69 (9–194) | |

SLND salvage lymph node dissection, SLNRT salvage lymph node radiotherapy, PSA prostate specific antigen, RPE radical prostatectomy, LN lymph node, RT radiotherapy

Data on Gleason score obtained from radical prostatectomy

Currences within in the prostatic fossa were irradiated with 70.0 Gy (range, 68–70 Gy) and PSMA PET-positive lymph nodes with 61.6 Gy (range, 50.4–66 Gy). Planning CT was done in supine position with 3 mm slice thickness. Patients were advised to have a full bladder and empty rectum. Target delineation was performed according to the Radiation Therapy Oncology Group (RTOG) atlas for salvage PCa [17] and for lymphatic pathway delineation [18].
Lymph node dissection

The standard SLND procedures at our department have been described before [7, 19]. Briefly, an open approach through an abdominal midline incision was used and standard extended SLND was performed based on specific regions according to the most recent PSMA PET findings. Dissected lymph nodes were classified based on the respective anatomic region. Routinely, dissected lymph nodes were immediately sent for histopathologic analysis and evaluated according to standard protocols (serial sectioning, 200μm slices).

Treatment application and follow-up

Treatment management following PSMA PET was documented for each patient. Follow-up time was defined as the interval in months between SLND/SLNRT and the last recorded PSA. Follow-up examination was first performed 6 weeks to 3 months after SLND/SLNRT and then every 6–12 months. Patients were regarded free of ADT influence after a minimum time-period of 5 months after last application of ADT.

Statistical analysis

BRFS (PSA ≤0.2 ng/ml) was defined as the primary study endpoint. For statistical analysis, SPSS Statistics 25 (IBM, New York, NY, USA) was used. Demographic data were analysed using descriptive statistics and χ2 test. Time to event data was calculated using the Kaplan–Meier method. Differences between subgroups were compared using log rank test with a p value of <0.05 considered statistically significant. The χ2 test, Mann–Whitney U test and binary logistic regression were performed to determine the influence of SLND vs. SLNRT, GS/DC4 6–7 vs. GS 8–9, tumour stage T2 vs. T3–4, nodal stage N0/N x vs. N1, D’Amico stage low/intermediate vs. high, PSA at salvage therapy, PSA persistence vs. PSA recurrence and PET-positive pelvic vs. pelvic and/or retroperitoneal lymph nodes on bRFS.

Results

Patients’ characteristics and PSMA PET results

Most patients (87/100; 87%) had a high-risk PCa at time of RPE with no significant difference between the SLND and SLNRT cohort. SLNRT patients had significantly more tumours with locally advanced pT3 or pT4 disease (82% vs. 67%; p = 0.006) compared to the SLND cohort with significantly more tumours of pT2 category (33% vs. 18%). Furthermore, there were significantly more patients in the SLNRT cohort with evidence of pathologically involved lymph nodes (45% vs. 27%; p = 0.001) and positive surgical margins (54% vs. 12%; p = 0.001) at time of RPE. Overall, there were 58 patients with PSA persistence and 42 patients with PSA recurrence after RPE. SLNRT for PET-positive lymph nodes was significantly more often applied in patients with PSA persistence (73%) than PSA recurrence (27%). On the other hand, SLND was performed significantly more often in patients with PSA recurrence (73%) than PSA persistence (67% vs. 69 months). Patients with SLND had only evidence of PET-positive lymph nodes (100%). Patients with SLNRT had PET-positive lymph nodes with (24%) or without (76%) local recurrence within prostatic fossa (p = 0.001). There was no significant difference in the distribution of PET-positive lymph nodes between the two cohorts: Only few patients had evidence of para-aortic lymph nodes (24% in the SLND group and 19% in the SLNRT group; p = 0.063).

Management of PET-positive lymph nodes and toxicity

Median PSA prior SLND was higher than prior SLNRT (3.07 ng/ml vs. 1.3 ng/ml; p = 0.393). Overall, a median of 8 (1–44) lymph nodes were removed at time of SLND. Evidence of PCa was pathologically confirmed in a median of 1 (0–16) lymph node. In total, there were 4 patients with a Clavien Grade II (2× paralytic ileus, 2× lymphorrhea) and 2 patients with a Clavien Grade IIIa (2× pulmonary artery embolism) complication (Table 2).

ADT was recommended to all patients with SLNRT due to the evidence of PET-positive lymph nodes for 2 years [20, 21]. Consequently, 59/67 (88%) patients were started on ADT before initiation of SLNRT, 42/67 patients (63%) discontinued after a median time of 7 (2–41) months due to patients’ preferences. Median time between end of ADT

| Table 2 | Treatment characteristics of salvage lymph node dissection cohort |
|---------|---------------------------------------------------------------|
| SLND    |                                                               |
| Median PSA before LN dissection | 3.07 (0.26–19.50) |
| Number of removed LN median (range) | 8 (1–44) |
| Number of positive LN median (range) | 1.0 (0–16) |
| Complications |                                                               |
| Intraoperative | 1 (3%) |
| Postoperative | 6 (18%) |
| Clavien | 4× Clavien II, 2× Clavien IIIa |

SLND salvage lymph node dissection, LN lymph node
Table 3  Treatment characteristics of radiotherapy cohort

| SLNRT |  |
|---|---|
| **SLNRT** |  |
| Median PSA before LN RT | 1.3 (0.10–40.13) |
| RT (Gy/median; range) |  |
| Former prostate | 66 (60–67.2) |
| Lymphatic pathways | 50.4 (45.0–52.28) |
| PET-positive local recurrence | 70 (68–70) |
| PET-positive LN | 61.6 (50.4–66) |
| **RT technique** |  |
| VMAT/IMRT & IGRT | 67 (100%) |
| ADT with RT | 59 (88%) |
| ADT with stop before last follow-up/median duration (months; range) | 42 (63%) |
| Ongoing ADT at last follow-up | 17 (25%) |
| No ADT | 8 (12%) |
| **Toxicity** |  |
| **Acute toxicity** |  |
| n (%) | Grade 2 | Grade 3 | Grade 4 |
| GU | 19 (28%) | 1 (2%) | – |
| GI | 19 (28%) | – | – |
| **Late toxicity** |  |
| n (%) | Grade 2 | Grade 3 | Grade 4 |
| GU | 17 (25%) | 1 (2%) | – |
| GI | 1 (2%) | – | – |
| **Other (erectile dysfunction)** |  |
| n (%) | 6 (9%) | 24 (36%) |

SLNRT salvage lymph node radiotherapy, ADT androgen deprivation therapy, RT radiation therapy, VMAT volumetric modulated arc therapy, IMRT intensity-modulated radiotherapy, IGRT image-guided radiotherapy, LN lymph node, GU genitourinary, GI gastrointestinal

and last follow-up was 27 months (range 0–48) in those patients with discontinued ADT. In all, 8/67 (12%) patients refused ADT. Patients received radiotherapy treatment as depicted above. Acute grade 2 gastrointestinal and urogenital toxicity were each observed in 19/67 (28%) patients consisting primarily of diarrhoea and increased urinary frequency. Acute grade 3 urogenital toxicity occurred in 1/67 (2%) patients with evidence of urethral stenosis. Late grade 2 toxicity was overall seen in 24/67 (36%) patients with mainly signs of erectile dysfunction and increased urinary frequency. Late grade 3 toxicity was present in 25/67 (37%) patients with mainly erectile dysfunction (36%) (Table 3).

Fig. 1  Biochemical recurrence-free survival in patients with salvage lymph node dissection (SLND) vs. salvage lymph node radiotherapy (SLNRT) after metastasis-directed therapy (MDT). mo months, HR hazard ratio, 95% CI 95% confidence interval
Table 4  Outcome after salvage lymph node dissection/salvage lymph node radiotherapy  

|                          | SLND cohort (n = 33) | SLNRT cohort (n = 67) | p-value |
|--------------------------|----------------------|-----------------------|---------|
| **Median follow-up**     | 17 (6–53)            | 31 (3–56)             | 0.027   |
| **Posttreatment PSA**    | 0.47 (<0.03–9.61)    | 0.05 (<0.03–19.0)     | 0.003   |
| **PSA at last follow-up**|                      |                       |         |
| Median PSA               | 2.50 (<0.03–68.0)    | 0.05 (<0.03–268)      | 0.025   |
| PSA ≤0.1 ng/ml           | 7 (21%)              | 46 (69%)              | 0.001   |
| PSA ≤0.2 ng/ml           | 10 (30%)             | 50 (75%)              | 0.001   |
| **Secondary treatment**  |                      |                       |         |
| (ADT, RT, sx)            | n = 25               | n = 42                |         |
| Median PSA               | 1.21 (<0.03–13.0)    | 0.06 (<0.03–268)      | 0.02    |
| PSA ≤0.1 ng/ml           | 5 (20%)              | 32 (76%)              | 0.001   |
| PSA ≤0.2 ng/ml           | 7 (28%)              | 34 (81%)              | 0.001   |
| **Tumour-related**       | 0                    | 1                     | 1.0     |

**SLND** salvage lymph node dissection, **SLNRT** salvage lymph node radiotherapy, **ADT** androgen deprivation therapy, **PSA** prostate specific antigen, **RT** radiotherapy, **sx** surgery

**Patient outcomes**

Median follow-up was 17 months (range, 6–53 months) in patients with SLND and 31 months (range, 3–56 months) in patients with SLNRT (p = 0.027). Median posttreatment PSA was significantly higher in patients with SLND (0.47 ng/ml, range <0.03–9.61 ng/ml) than in patients with SLNRT (0.05 ng/ml, range <0.03–19 ng/ml) (p = 0.003). At last follow-up, median PSA was 2.50 ng/ml (range <0.03–68 ng/ml) in patients with SLND and 0.05 ng/ml (range <0.03–268 ng/ml) in patients with SLNRT (p = 0.025). Overall, the 2-year bRFS was significantly higher in the SLNRT cohort compared to the SLND cohort (92% vs. 30%; p = 0.001) irrespective of ongoing androgen deprivation therapy at last contact (Fig. 1; Table 4). This resulted in a significantly higher rate of distant metastases (52% vs. 21%; p = 0.002) and secondary treatments (39% vs. 15%; p = 0.011) in patients with SLND. There was one tumour-related death in the SLNRT group.

In multivariable analysis stratified for Gleason score at RPE and PSA prior to PSMA PET/CT, SLND vs. SLNRT was significantly associated with bRFS (regression coefficient 1.473, hazard ratio 4.360, 95% CI 1.665–11.418; p = 0.003) (Table 5 and Supplemental Table 1).

**Discussion**

Management of lymph node recurrence after RPE is a challenging clinical scenario, and there is sparse comparative data regarding the beneficial effects of SLND and SLNRT on survival outcomes. Integration of existing evidence is further hampered by differing patient characteristics, diagnostic modalities and therapy sequences [4]. Overall, it is hypothesized that MDT to lymph node recurrences optimizes the locoregional control, possibly limits the risk of distant progression and thereby might improve cancer-specific survival, as has been described by mainly retrospective data [22–26].

In the current study, bRFS of a contemporary patient cohort diagnosed with PSMA PET-positive nodal recurrence of PCa after RPE is provided. To further homogenize the

Table 5  Multivariate analysis of factors associated with biochemical recurrence-free survival after salvage lymph node dissection/salvage lymph node radiotherapy  

| Association with bRFS (<0.2 ng/mL) | Regression coefficient | HR    | 95% CI          | p-Valuea |
|-----------------------------------|------------------------|-------|-----------------|----------|
| SLND vs. SLNRT                    | 1.473                  | 4.360 | 1.665–11.418    | 0.003    |
| GS ≤6–7 vs. GS 8–9                | 1.063                  | 0.345 | 0.135–0.883     | 0.027    |
| PSA at salvage therapy [ng/ml]    | 0.064                  | 1.066 | 0.991–1.147     | 0.087    |

aBinary logistic regression

**SLND** salvage lymph node dissection, **SLNRT** salvage lymph node radiotherapy, **bRFS** biochemical recurrence-free survival, **GS** Gleason Score, **PSA** prostate specific antigen, **HR** hazard ratio, **95% CI** 95% confidence interval
present patient cohort, none of the included patients had ADT or adjuvant radiotherapy of the pelvic lymphatic pathways prior to SLND/SLNRT. In total, 100 patients (n = 33 SLND, n = 67 SLNRT) were included in the final analysis, of whom all SLNRT patients were treated with ENRT with simultaneous integrated boost (SIB) to the PET-positive lymph nodes. All surgically treated patients received a standard extended SLND. Regarding the patient characteristics, there were some noticeable differences between the SLND and the SLNRT subgroup. First, patients undergoing SLNRT had a significantly higher proportion of nonorgan confined disease as well as positive surgical margins at the time of RPE compared to SLND patients. As expected, patients with SLND were primarily patients with PSA recurrence (73%), whereas the SLNRT cohort encompassed mostly patients with biochemical persistence (73%). Finally, based on GS score, there was a trend towards more high-risk patients in the SLNRT patient cohort without reaching statistical significance. Even though relevant differences between the two patient subgroups cannot be overlooked, these patients represent typical contemporary patient cohorts in tertiary care centres. Hereby, the SLNRT cohort had overall worse inherent features compared to the SLND cohort. Nevertheless, bRFS was significantly longer in the SLNRT cohort compared to the SLND cohort irrespective of ongoing ADT at the timing of last follow-up. Furthermore, patients of the SLND cohort had a significantly higher rate of distant metastases and need of secondary treatments.

Rischke et al. reported on a similar analysis of 93 patients with exclusively nodal PCa relapse, but staged with choline PET/CT who were either treated by SLND alone (46 patients) or SLND followed by RT (47 patients) to the regions with proven lymph node metastases [27]: Additional RT led to a significant delayed relapse within the treated region (5-year relapse-free rate 70.7% vs. 26.3%), while time to next relapse outside the treated region was almost equal (median 27 months vs. 29.6 months). Furthermore, patients treated with both modalities had significantly lower rates of new recurrent pelvic lymph node metastases compared to patients with surgery only (13% vs. 57.6%). Although, staged with prostate treatment and the PEACE V trial (NCT03569241) that includes patients with 1–5 pelvic nodal oligorecurrent PCa in relation to different surgical (limited, standard, superextended SLND) and radiotherapy templates. Correspondingly, they found that with ENRT more patients were theoretically fully covered (p < 0.02) and the total number of covered lesions was higher (p < 0.001) when compared to all types of SLND, except for superextended SLND, which was comparable to ENRT. The authors concluded that limited or standard extended SLND might be insufficient as a salvage treatment approach and ENRT or superextended SLND should be preferred [33].

MDT to recurrent lymph node metastases is still controversial and there is an ongoing debate whether it definitely changes the disease outcome in the long-run or represents just “PSA cosmetics” that comes at a cost of potential toxicity [34]. Clearly, its oncologic benefit is dependent on patient selection. Fossati et al. evaluated 654 patients with nodal recurrence after RPE who underwent SLND: At multivariable analysis, Gleason grade group 5, time from RPE to PSA rising, ADT application at PSA rising after RPE, retroperitoneal or three or more spots at PET/CT scan and PSA level at SLND were significant predictors of clinical recurrence after SLND [35].

Ongoing clinical trials, such as OLIGOPELVIS (NCT02274779) that includes patients with 1–5 pelvic nodal oligometastases who are treated with high-dose radiotherapy and ADT for 6 months after prior radical prostate treatment and the PEACE V trial (NCT03569241) that randomizes patients with ≤3 oligorecurrent pelvic lymph node metastases between MDT with 6 months of ADT alone versus MDT with 6 months of ADT and whole pelvis RT will further help to optimize the therapy.
tic approach in patients with oligometastatic lymph node recurrences and are eagerly awaited.

Head-to-head comparisons of SLND to SLNRT, as was performed in the current study, give an insight of what might be the optimal treatment for patients with pelvic lymph node recurrences but are not without limitations. First, it has to be stated that the median follow-up was shorter for the SLND cohort. This might result in an underestimation of the real therapeutic effects of the two different treatment modalities. Second, this analysis was not performed as a matched pair analysis due to the small patient number. Third, bRFS is not the optimal endpoint as it is influenced by ADT use and 88% of SLNRT patients received ADT concomitantly with RT. This might lead to a more favourable bRFS in some patients, although the majority (50/67; 75%) had no ADT at last follow-up and 42/59 (71%) of those with ADT concomitantly to RT had discontinued it a median of 27 months (range 0–48 months) before last follow-up. Fourth, none of SLND patients has received postoperative adjuvant radiotherapy due to locally advanced tumour or positive surgical margins posing an undertreatment. This might partly explain the lower bRFS in SLND patients and might lead to the conclusion that SLND should primarily be undertaken in patients without locally advanced disease or positive surgical margins when adjuvant radiotherapy of prostatic fossa is withheld.

The aim of this comparative study was to explore the possible treatment options for patients with PSMA PET-positive, oligorecurrent nodal disease: With all its inherent flaws of such an retrospective analysis, SLNRT seems to be the preferred treatment option for patients with nodal recurrences after previous radical prostatectomy especially when undergoing a combination of SLNRT in the form of an ENRT as it is performed in our institution and concomitant ADT with overall an acceptable toxicity profile. The present results cannot be transferred to other surgical approaches like superextended SLND. Even though all patients received PSMA PET-guided MDT [36], one can state that with the current imaging modalities, also at the time of PSMA PET/CT a more restricted surgical or radiotherapy approach, like SBRT with the aim of less toxicity cannot be safely performed yet. Despite its limitations, the current study depicts real-world data from a tertiary-care reference centre and might be hypotheses-generating for future phase II trials.

Conclusions

In the current study, rare comparative data from a contemporary patient cohort diagnosed within the PSMA-PET/CT era are provided. Significant differences regarding patient characteristics were observed that must be considered for future trial design. Overall, in this retrospective study a longer bRFS was observed in patients undergoing PSMA PET-informed SLNRT as compared to SLND for lymph node recurrent PCa. Findings need to be confirmed in a prospective randomized trial.

Author Contribution All authors contributed to the conception and design of the retrospective study, data acquisition, analysis and interpretation of the data. All authors were involved in drafting and revising the manuscript. All authors have given their stamp of approval for the submission of this manuscript.

Funding Open Access funding provided by Projekt DEAL.

Conflict of interest N.-S. Schmidt-Hegemann, A. Buchner, C. Eze, P. Rogowski, C. Schaefer, H. Ilhan, M. Li, P. Bartenstein, U. Gaswintd, C. Stief, C. Belka and A. Kretschmer declare that they have no competing interests. W. P. Fendler is consultant for Endocyte, Ipsen and RadioMedix. W. P. Fendler received financial support from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG, grants FE1573/1-1/807122 and FE1573/3-1/659216), Mercator Research Center Ruhr (MERCUR, An-2019-0001), IFORES (D/107-81260, D/107-30240), Doktor Robert Pfleger-Stiftung, and Wiedenfeld-Stiftung/Stiftung Krebsforschung Duisburg.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG et al (2016) Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937
2. Calais J, Czerinn J, Cao M, Kishan AU, Hegde JV, Shaverdian N et al (2018) 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0ng/mL: Impact on salvage radiotherapy planning. J Nucl Med 59:230–237
3. Henkenberens C, von Klot CA, Ross TL, Bengel FM, Wester JH, Merseburger AS et al (2016) (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : early efficacy after primary therapy. Strahlenther Onkol 192:431–439
4. Ploussard G, Gandaglia G, Borgmann H, de Visschere P, Heidegger I, Kretschmer A et al (2019) Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review. Eur Urol 76:493–504
5. De Bleser E, Tran PT, Ost P (2017) Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Curr Opin Urol 27:587–595
6. Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M (2011) [18F]fluoroethylcholine-PET/CT imaging for radiation treatment
planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol 6:44
7. Herlemann A, Kretschmer A, Buchner A, Karl A, Tritschler S, El-Malazi L et al (2017) Salvage lymph node dissection after (68)Ga-PSMA or (18)F-FEC PET/CT for nodal recurrence in prostate cancer patients. Oncotarget 8:84180–84192
8. Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C et al (2016) (68)Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 70:553–557
9. van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B et al (2016) (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostastic fossa in patients being considered for salvage radiation treatment. BJU Int 117:732–739
10. Walacides D, Meier A, Knöchelmann AC, Meinecke D, Derlind T, Bengel FM et al (2019) Comparison of (68)Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer. Strahlenther Onkol 195:420–429
11. Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S et al (2018) The impact of [68Ga]PSMA I&T PET/CT on radiotherapy planning in patients with prostate cancer. Strahlenther Onkol 194:646–654
12. D’Amico AV, Whittington R, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A (1997) Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol 158: 1422–1426
13. General Assembly of the World Medical Association (2014) World medical association declaration of helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent 81:14–18
14. Weineisen M, Simecek J, Schottelius M, Schwager M, Wester HJ (2014) Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res 4:63
15. Fendler WP, Eiber M, Behehti M, Bomanji J, Ceci F, Cho S et al (2017) (68)Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging; version 1.0. Eur J Nucl Med Mol Imaging 44:1014–1024
16. Daube-Witherspoon ME, Karp JS, Casey ME, DiFilippo FP, Rines H, Muellerlehner G et al (2002) PET performance measurements using the NEMA NU 2-2001 standard. J Nucl Med 43:1398–1409
17. RTOG Foundation (2020) Prostate post-op. https://www.rtog.org/CoreLab/ContouringAtlases/ProstatePostOp.aspx. Accessed 29 Jan 2018
18. Lawton CAF, Michalski J, El-Naqa I, Buzyounouski MK, Lee WR, Menard C et al (2009) RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 74:383–387
19. Tilki D, Mandel P, Seeliger F, Kretschmer A, Karl A, Ergun S et al (2015) Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. J Urol 193:484–490
20. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ et al (2017) Radiation with or without androgen therapy in recurrent prostate cancer. N Engl J Med 376:417–428
21. Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Gandaglia G, De Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, Van As N, Ost P et al (2015) Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. J Urol 194:983–988
22. Rischke HC, Schultze-Seemann W, Wieser G, Krönig M, Drendel V, Stegmaier P et al (2015) Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol 191:310–320
23. Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS et al (2019) 99mtechnetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur Urol 75:659–666
24. Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J et al (2019) Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 74:455–462
25. Ost P, Reynolds D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36:446–453
26. Abdollah F, Dalela D, Sood A, Kleeby J, Alane S, Briganti A et al (2018) Impact of adjuvant radiotherapy in node-positive prostate cancer patients: the importance of patient selection. Eur Urol 74:253–256
27. Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K et al (2018) Standard of care versus metastasis-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. Eur Urol Focus. https://doi.org/10.1016/j.euf.2018.02.015
28. Ploussard G, Almeras C, Briganti A, Giannarini G, Hennequin C, Ost P et al (2015) Management of node only recurrence after primary local treatment for prostate cancer: an updated clinical review. J Urol 194:983–988
29. Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS et al (2019) 99mtechnetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur Urol 75:659–666.
30. Sirriwardana A, Thompson J, van Leeuwen PJ, Doig S, Kalsbeek A, Emmett L et al (2017) Initial multicentre experience of 68gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU Int 120:673–681
31. Rauscher I, Düwel C, Wirtz M, Schottelius M, Wester HJ, Schwamborn K et al (2017) Value of 111In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. BJU Int 120:40–47
32. De Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, Van As N, Siva S et al (2019) Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol. https://doi.org/10.1016/j.euro.2019.07.009
33. Hope TA, Goodman JZ, Allen JE, Calais J, Fendler WP, Carroll PR (2019) Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med 60:786–793
34. De Bruycker A, De Bleser E, Decaestecker K, Fonteyne V, Lumen N, De Visschere P et al (2019) Nodal oligorecurrent prostate cancer: anatomic pattern of possible treatment failure in relation to elective surgical and radiotherapy treatment templates. Eur Urol 75:826–833
35. Murphy DG, Sweeney CJ, Tombal B (2017) “Gotta catch ’em all”, or do we? Pokemon approach to metastatic prostate cancer. Eur Urol 72:1–3
36. Fossati N, Suardi N, Gandaglia G, Braiv CR, Soligo M, Karnes RJ et al (2019) Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis. Eur Urol 75:176–183
37. Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q et al (2015) Prospective comparison of 18F-fluoromethylcholine versus 68ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 56:1185–1190
Affiliations

Nina-Sophie Schmidt-Hegemann1 · Alexander Buchner2 · Chukwuka Eze1 · Paul Rogowski1 · Christian Schaefer1 · Harun Ilhan3 · Minglun Li1 · Wolfgang Peter Fendler4 · Peter Bartenstein3 · Ute Ganswindt5 · Christian Stief2 · Claus Belka1,6 · Alexander Kretschmer2

PD Dr. med. Alexander Buchner
Alexander.Buchner@med.uni-muenchen.de

Dr. med. Chukwuka Eze
Chukwuka.Eze@med.uni-muenchen.de

Christian Schaefer
Christian.Schaefer@med.uni-muenchen.de

Dr. med. Harun Ilhan
Harun.Ilhan@med.uni-muenchen.de

Dr. med. Minglun Li
Minglun.Li@med.uni-muenchen.de

PD Dr. med. Wolfgang Peter Fendler
Wolfgang.Fendler@uk-essen.de

Prof. Dr. med. Peter Bartenstein
Peter.Bartenstein@med.uni-muenchen.de

Prof. Dr. med. Ute Ganswindt
ute.ganswindt@i-med.ac.at

Prof. Dr. med. Christian Stief
Christian.Stief@med.uni-muenchen.de

Prof. Dr. med. Claus Belka
Claus.Belka@med.uni-muenchen.de

PD Dr. med. Alexander Kretschmer
Alexander.Kretschmer@med.uni-muenchen.de

1 Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany

2 Department of Urology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany

3 Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany

4 Department of Nuclear Medicine, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany

5 Department of Therapeutic Radiology and Oncology, Innsbruck Medical University, Anichstr. 35, 6020 Innsbruck, Austria

6 German Cancer Consortium (DKTK), Munich, Germany